Characteristics of Patients With Type 2 Diabetes Mellitus (CVD-RNDR)

AstraZeneca

Status: Completed

Conditions: Type 2 Diabetes

Study type: Observational

Funder types: Industry

Identifiers

NCT03694470

D1690R00048

Details and patient eligibility

About

This observational retrospective study will describe characteristics of patients with type 2 diabetes mellitus (T2DM) who were initiating use or treatment with sodium-glucose co-transporter-2 (SGLT-2) inhibitors and other diabetes medications (other glucose lowering drugs) in 2015-17 based on National Russian Diabetes Registry data.

Enrollment: 10,000 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria are:

• New user receiving or dispensed prescription of SGLT-2 inhibitor medication or other GLD treatments oral as well as injectable, including fixed-dose combination (FDC) products containing these medication groups;
• T2DM diagnosis on or prior to the index year;
• ≥ 18 years old at index year.

Exclusion criteria are:

• Patients with a T1DM diagnosis on or prior to index year and only insulin use in the year prior to index;
• Patients with a gestational diabetes in the index year or 1 year prior to index.